Mamma carcinoma

Title Study Year Journal/Event
Prophylaxis of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with breast cancer: results from an interim analysis of the non-interventional study NADIR.

Fietz T, Kurbacher CM, Trarbach T, Salat C, Rezai M, Lorenz A, et al. Oncol Res Treat. 2016;39 (suppl5)(P952):xx.

NADIR 2016 DGHO
Efficacy and safety of nab-paclitaxel in patients with metastatic breast cancer: Final results of the non-interventional study NABUCCO.

Marschner N, Potthoff K, Salat C, Söling U, Hansen R, Grebhardt S, et al. Oncol Res Treat. 2016;39 (suppl5)(P598):xx.

NABUCCO 2016 DGHO
Patient-reported outcomes of 905 patients with breast cancer two years after start of curative systemic treatment.

Marschner N, Trarbach T, Dörfel S, Meyer D, Müller-Hagen S, Zaiss M, et al. Oncol Res Treat. 2016;39 (suppl.5)(V385).

TMK 2016 DGHO
Efficacy and safety of nab-paclitaxel in patients with metastatic breast cancer: Final results of the non-interventional study NABUCCO.

Potthoff K, Nusch A, Söling U, Hansen R, Salat, Grebhardt S, et al. Ann Oncol. 2016;(3955).

NABUCCO 2016 ESMO
Prohylaxis of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with breast cancer: results from an interim analysis of the non-interventional study NADIR.

Kurbacher C, Fietz T, Trarbach T, Salat C, Rezai M, Lorenz A, et al. Ann Oncol. 2016;(992).

NADIR 2016 ESMO
Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial.

Welt A, Marschner N, Lerchenmueller C, Decker T, Steffens C-C, Koehler A, et al. Breast Cancer Res Treat. 2016 Feb;156(1):97-107.

CARIN 2016 Breast Cancer Res Treat
Wechselnde Symptombelastung – gleichbleibende Lebensqualität? – Longitudinale Daten des MaLife-Projekts zu Patientinnen mit metastasiertem Mammakarzinom unter Monochemo- bzw. Hormontherapie.

Marschner N, Nusch A, Decker T, Münz M, Kruggel L, Jänicke M. Senologie – Zeitschrift für Mammadiagnostik und -therapie. 27. Mai 2016;2(13):P074.

TMK 2016 Senologie-Kongress
Efficacy of trastuzumab re-therapy in the clinical routine of HER2-positive breast cancer patients who relapsed after completed anti-HER2 (neo)adjuvant therapy with trastuzumab – 5th interim analysis of the national non-interventional study (NIS).

Hanker LC, Hitschold T, Grafe A, Förster F, Schröder J, Janssen J, Reichert D, Hielscher C, Keitel S, Hesse T. ML21589

Herceptin-NIS 2015 SABCS
Osteoprotektive Behandlung von Patientinnen mit ossär metastasiertem Mammakarzinom – Daten zur Behandlungsrealität aus dem Tumorregister Mammakarzinom.

Köhler A, Tesch H, Nusch A, Fietz T, Kruggel L, Spring L, et al. Senologie – Zeitschrift für Mammadiagnostik und -therapie. 2015 May 22;12(02):A77.

TMK 2015 Senologie-Kongress
No impact of increasing symptoms on quality of life? Longitudinal data from the German MALIFE-Project on patients receiving monochemo- and endocrine treatment for advanced breast cancer – results from the TMK registry group.

Marschner N, Nusch A, Decker T, Münz M, Kruggel L, Jänicke M. The Breast. 2015;24 (suppl3)(OR51):S39.

TMK 2015 ABC3
Final efficacy and safety analysis of the CARIN phase III trial: Cap and Bev with or without Vin in 1st line metastatic breast cancer (MBC).

Welt A, Marschner N, Lerchenmüller C, Decker T, Salat C, Busies S, et al. Ann Oncol. 2014;25(suppl 4):iv119 (359PD).

CARIN 2014 ESMO
No impact of increasing symptom burden on quality of life? – Longitudinal data from the German MaLife-Project on patients receiving monochemo- and endocrine treatment for metastatic breast cancer.

Marschner N, Nusch A, Decker T, Münz M, Kruggel L, Jänicke M. Oncol Res Treat. 2015;38 (suppl 5)(V670):202.

TMK 2015 DGHO
Prophylactic treatment of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with breast cancer: subgroup analysis of the non-interventional study NADIR.

Kurbacher C, Fietz T, Salat C, Zaiss M, Gazawi N, Steffens C-C, et al. Oncol Res Treat. 2015;38 (suppl 5)(P255):77-78.

NADIR 2015 DGHO
Final efficacy and safety analysis of the CARIN phase III trial: Cap and Bev with or without Vin in 1st line metastatic breast cancer (MBC).

Welt A, Marschner N, Lerchenmüller C, Decker T, Salat C, Busies S, et al. Ann Oncol. 2014;25(suppl 4):iv119 (359PD).

CARIN 2014 ESMO
No impact of first-line systemic therapy on quality of life of patients with metastatic breast cancer? Data from the MaLife-project;

Marschner, N.; Tesch, H.; Karcher, A.; Ammon, A.; Nusch, A.; Boller, E.; Spring, L.; Jänicke, M.; OncolResTreat 2014; 37(suppl.5)(V371)

TMK 2014 DGHO
Chemotherapy, targeted therapy and anti-hormonal therapy of elderly patients with breast cancer – data from the SENORA project;

Zahn, M.-O., Tesch, H.; Köhler, A., Fietz, T., Münz, M., Kruggel, L., Jänicke, M. und Marschner, N.; OncolResTreat 2014; 37(suppl.5)(V374)

TMK 2014 DGHO
Long-term side effects of curative treatment for breast cancer – data from the MaTox project;

Hurtz, H.-J.; Tesch, H.; Göhler, T.; Hutzschenreuther, U.; Harde, J.; Kruggel, L.; Marschner, N.; OncolResTreat 2014; 37(suppl.5)(V370)

TMK 2014 DGHO
Efficacy of anti-HER2 ReTherapy with Herceptin® at first relapse and/or first occurrence of metastases of HER2-positive breast cancer in clinical routine – 4th interim analysis of the non-interventional study (NIS) ML21589.

Hanker L, Hitschold T, Grafe A, Förster F, Schröder J, Janssen J, et al. Annals of Oncology. 2014;25(suppl4)(400P).

Herceptin-NIS 2014 ESMO
Wirksamkeit erneuter Anti-HER2-Therapie mit Herceptin® in der klinischen Routine bei erstem Rezidiv und/oder erster Metastasierung des HER2-positiven Mammakarzinoms – 4. Interimanalyse der ichtinterventionellen Studie (NIS) ML21589.

Hanker L, Hitschold T, Grafe A, Förster F, Schröder J, Janssen J, et al. Senologie – Zeitschrift für Mammadiagnostik und -therapie. 2014;11:A50.

Herceptin-NIS 2014 Senologie-Kongress
Primary efficacy endpoint analysis of the CARIN trial: Capecitabine (Cap) and bevacizumab (Bev) with or without vinorelbine (Vin) in first line metastatic breast cancer (MBC).

Welt A, Lerchenmüller C, Decker T, Marschner N, Salat C, Hegewisch-Becker S.2013;P3-13-01.

CARIN 2013 SABCS
Overall survival and sequential treatment of patients with metastatic breast cancer treated by German office-based medical oncologists – outcome data from the TMK Registry Group.

Marschner N, Däßler K-U, Müller-Hagen S, Kruggel L, Jänicke M, Tesch H. The Breast. 2013;22 (suppl 3)(V39).

TMK 2013 ABC2
Effectiveness of taxane- or anthracyclin-based compared to taxane- and anthracycline-free first-line treatments of patients with metastatic breast cancer treated by German office-based medical oncologists. Data from the TMK Registry Group.

Marschner N, Dörfel S, Meyer D, Petersen V, Frank M, Jänicke M, u. a. The Breast. 2013;22 (suppl 3)(P41).

TMK 2013 ABC2
Chemotherapeutische und zielgerichtete Behandlung bei älteren Patientinnen mit Mammakarzinom – Daten aus dem ELDERLY Projekt.

Otremba B, Tesch H, Köhler A, Jänicke M, Marschner N. Senologie – Zeitschrift für Mammadiagnostik und -therapie 2013;10(02).

TMK 2013 Senologie-Kongress
Can we learn anything from clinical tumour registries?

Marschner N. Onkologie. 2013;36 (Suppl 7)(V890).

TMK 2013 DGHO
Overall survival and sequential treatment of patients with metastatic breast cancer treated by German office-based medical oncologists – outcome data from the TMK Registry.

Tesch H, Däßler K, Müller-Hagen S, Kruggel L, Jänicke M, Marschner N. Onkologie. 2013;(V358).

TMK 2013 DGHO
Chemotherapy and targeted therapy of elderly patients with breast cancer – data from the ELDERLY project.

Otremba B, Tesch H, Köhler A, Jänicke M, Marschner N. Onkologie. 2013;(V354).

TMK 2013 DGHO
Quality of life in the first weeks of (neo)adjuvant systemic therapy of patients with breast cancer – first data from MaLife, a pilot project of the TMK Registry Group.

Marschner N, Tesch H, Behringer J, Sandner R, Spring L, Jänicke M. Onkologie. 2013;(V355).

TMK 2013 DGHO
Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis.

Fontein DBY, Seynaeve C, Hadji P, Hille ETM, van de Water W, Putter H, u. a. J Clin Oncol. 2013;31(18):2257–64.

TEAM 2013 J Clin Oncol
Elderly postmenopausal patients with breast cancer are at increased risk for distant recurrence: a tamoxifen exemestane adjuvant multinational study analysis.

Fontein DBY, Seynaeve C, Hadji P, Hille ETM, van de Water W, Putter H, u. a. Oncologist. 2013;18(1):8–13.

TEAM 2013 Oncologist
Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2 therapy.

Hanker L, Hitschold T, Hesse T, Grafe A, Förster F, Schröder J, u. a. J Clin Oncol. 2013;31(suppl; abstr 602).

Herceptin-NIS 2013 ASCO
Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer.

Van de Water W, Markopoulos C, van de Velde CJH, Seynaeve C, Hasenburg A, Rea D, u. a. JAMA. 2012;307(6):590–7.

TEAM 2012 JAMA
Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM.

Hadji P, Kieback DG, Tams J, Hasenburg A, Ziller M. Ann Oncol. 2012;23(10):2566–72.

TEAM 2012 Ann Oncol
Effects of exemestane and tamoxifen on hormone levels within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German substudy.

Hadji P, Kauka A, Bauer T, Tams J, Hasenburg A, Kieback DG.Climacteric. 2012;15(5):460–6.

TEAM 2012 Climacteric
Compliance, analgesic use and side-effect protection within a German cohort of the TEAM trial.

Bossart M, Becker M, Hadji P, Kieback DG, Hasenburg A. Anticancer Res. 2012;32(9):3933–8.

TEAM 2012 Anticancer Res
Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study.

Bartlett JMS, Bloom KJ, Piper T, Lawton TJ, van de Velde CJH, Ross DT, u. a. J Clin Oncol. 2012;30(36):4477–84

TEAM 2012 J Clin Oncol
Effectiveness of taxane- or anthracylin-based compared to taxane- and anthracyline-free 1st-line treatments in metastatic breast cancer patients in German oncology outpatient centres. Data from the clinical TMK Registry.

Marschner N, Tesch H, Dörfel S, Meyer D, Petersen V, Jänicke M. Onkologie. 2012;35(suppl 6):64

TMK 2012 DGHO
Behandlungsrealität in Deutschland: Daten aus dem Klinischen Tumorregister Mammakarzinom.

Marschner N. DKK, Berlin; 2012.

TMK 2012 DKK
Erneute Anti-HER2-Therapie mit Herceptin® beim ersten Rezidiv des HER2-positiven Mammakarzinoms – 1. Interimsanalyse der nichtinterventionellen Studie (NIS) ML21589.

Hanker, L., Prange-Krex, G., Janssen, J., Reichert, D., Schröder, J., Förster, F., Schnohr, S., u. a. (2012). Senologie – Zeitschrift für Mammadiagnostik und -therapie, 9(02). doi:10.1055/s-0032-1313426

Herceptin-NIS 2012 Senologie-Kongress
Reduced HFSR incidence observed in a randomized phase II study in advanced breast cancer patients treated with sorafenib and paclitaxel by initial ramp-up dose escalation (PASO).

Overkamp F, Steffens C-C, Abenhardt W, Lerchenmüller C, Nusch A, Göhler T, u. a. J Cancer Res Clin Oncol. 2012;138(Suppl. 1, Abstract 0026):62.

PASO 2012 DKK
Quality of life (QoL) in patients with metastatic breast cancer (MBC) treated with capecitabine – second interim analysis of the German non-interventional study (NIS).

Steffens C, Zaiss, Lerchenmüller C, Luhn B, Vehling-Kaiser U, Marschner N, u. a. J Cancer Res Clin Oncol. 2012;138(Suppl. 1, Abstract 0085):67.

Xeloda-NIS 2012 DKK
Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial.

Bartlett JMS, Brookes CL, Robson T, van de Velde CJH, Billingham LJ, Campbell FM, u. a. J Clin Oncol. 2011 Apr 20;29(12):1531–8.

TEAM 2011 J Clin Oncol
Networking Against Cancer.

Marschner N, Jänicke M. Breast Care. 2011;6(3):245–7.

Registerübergreifend 2011 Breast Care
Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer.

Stemmler HJ, Digioia D, Freier W, Tessen HW, Gitsch G, Jonat W, u. a. Br J Cancer. 2011 März 29;104(7):1071–8.

Gemcitabine 02 MC 2011 BrJ Cancer
Capecitabine (Cap) combined with bevacizumab (Bev) with or without vinorelbine (Vin) in first-line metastatic breast cancer (MBC): First safety results from the randomized CARIN trial.

Hegewisch-Becker S, Lerchenmüller C, Welt A, Decker T, Just M, Steffens C, u. a. J Clin Oncol (Meeting Abstracts). 2011;29(suppl; abstract 1044).

CARIN 2011 ASCO
Diabetes and breast cancer. Data from a clinical registry – TMK Registry.

Tesch H, Rauh J, Fietz T, Overkamp F, Hartmann H, Marschner N. Onkologie. 2011;34 (Suppl.6):189.

TMK 2011 DGHO
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.

van de Velde CJ., Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, u. a. Lancet. 2011;377(9762):321–31.

TEAM 2011 Lancet
Trends in surgical treatment of breast cancer. Data from a clinical registry.

Tesch H, Rauh J, Fietz T, Overkamp F, Hartmann H, Marschner N. Onkologie. 2010;33, Sup. 6:54.

TMK 2010 DGHO
The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies.

Hadji P, Asmar L, van Nes JGH, Menschik T, Hasenburg A, Kuck J, u. a. J Cancer Res Clin Oncol [Internet]. 2010

TEAM 2010 J Cancer Res Clin Oncol
Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a prospective gynecological ultrasound substudy.

Kieback DG, Harbeck N, Bauer W, Hadji P, Weyer G, Menschik T, u. a. Gynecol. Oncol. 2010 Dez;119(3):500–5.

TEAM 2010 Gynecol Oncol
Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries.

van Nes JGH, Seynaeve C, Jones S, Markopoulos C, Putter H, van de Velde CJH, u. a. Br J Surg. 2010 Mai;97(5):671–9.

TEAM 2010 BrJ Surg
Interim analysis of the German non-interventional post marketing surveillance study (NIS) on Quality of Life (QoL) of capecitabine in patients with metastatic breast cancer (MBC).

Zaiss M, Fuxius S, Lerchenmueller C, Hahn L, Luhn B, Marschner N, u. a. Ann Oncol. 2010;21 (suppl 8)(314P):viii108.

Xeloda-NIS 2010 ESMO
Gemcitabine plus vinorelbine versus gemcitabine plus cisplatin versus gemcitabine plus capecitabine: A randomized trial in pretreated metastatic breast cancer.

Freier W, Stemmler H-J, Tessen H-W, Gitsch G, Jonat W, Bruger W, u. a. Onkologie. 2009;32 (suppl 4):164.

Gemcitabine 02 MC 2009 DGHO
Use of Lenograstim in Daily Routine in German Outpatient Cancer Centres.

Schröder J, Eschenburg H, Söling U, Nacak T, Heinisch H. Onkologie. 2009;32 (suppl 4):142.

LENO 2009 DGHO
The treatment of breast cancer in German outpatient centres. Data from a clinical registry. A joint project of the AIO and the AKS.

Tesch H, Rauh J, Petersen V, Schröder J, Hartmann H. Onkologie. 2009;32 (suppl 4):66–7.

TMK 2009 DGHO
Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy.

Hadji P, Ziller M, Kieback DG, Dornoff W, Tessen HW, Menschik T, u. a. Ann Oncol [Internet]. 2009 Feb 13

TEAM 2009 Ann Oncol
The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.

Hadji, P., Ziller, M., Kieback, D. G., Menschik, T., Kalder, M., Kuck, J., & Hasenburg, A. (2009). Breast (Edinburgh, Scotland), 18(3), 159–164. doi:10.1016/j.breast.2009.03.003

TEAM 2009 Breast
A prospective planned pathology study within the TEAM trial confirms that progesterone receptor expression is prognostic but not predictive for differential response to exemestane versus tamoxifen.

Bartlett J, Brookes C, Billingham L, Campell F, Gnant M, Hasenburg A, u. a. 2008. p. 81.

TEAM 2008 SABCS
Bone Effects of Exemestane vs. Tamoxifen within the German TEAM trial: Results of a Prospective Randomized Bone Sub-Study (S. 1143).

Hadji, P., Ziller, M., Kieback, D., Dornoff, W., Tessen, H., Kuck, J., & Hasenburg, A. (2008). Gehalten auf der SABCS (San Antonio Breast Cancer Symposium).

TEAM 2008 SABCS
Results of the first planned analysisof the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausalearly breast cancer.

Jones SE, Seynaeve C, Hasenburg A, Rea D, Vannetzel JM, Paridaens R, u. a. 2008. p. 15.

TEAM 2008 SABCS
Quality of life in relation to endocrine treatment of postmenopausal women in the Dutch subset of the TEAM Trial.

van Nes J, Voskuil D, Putter H, van Leeuwen F, Junggeburt J, Hille E, u. a. 2008. p. 21.

TEAM 2008 SABCS

Merken

iOMEDICO AG
Hanferstraße 28
D-79108 Freiburg

Phone: 0761 - 15 242 0
E-Mail: info@iomedico.com